Lilly's Loxo Bet Pays Off In Thyroid Cancer, A Second Indication For Selpercatinib

 
• By Mandy Jackson
  
Thyroid-cancer
Lilly will seek approval in RET-mutant medullary thyroid cancer. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D